I continue to follow these threads on AVH--not because they are informative ,more so entertaining.
I fully endorse Gaucau's views on the potential. I have no doubt this Company will succeed and be acquired once the alternative product applications (vitilago, DVU/DFU, cosmetics)are proven and rolled out.
In the interim it will be a slow build in value as the Burns application and adoption grows not only in the US markets but Japan/Europe. Recell is truly a disruptive biotech.
However I too remain frustrated and annoyed at the approach adopted by Perry.
He has a quality CV and track record it appears however; he came in late to the CEO role (FDA was all but done prior to his appointment) and he has been over compensated with incentive shares.
As noted; there appears to be a pattern of positive market updates, an allotment of incentives and yes, the sell down for "tax purposes".
I don't recall ever seeing a CEO sell on EVERY allotment of incentives. We are overcompensating him and we are effectively paying his tax for him......Not happy.
- Forums
- ASX - By Stock
- AVH
- Ann: Change of Director's Interest Notice - Michael Perry
Ann: Change of Director's Interest Notice - Michael Perry, page-16
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 980 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 10173 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2500 | 2.780 |
3 | 2504 | 2.760 |
3 | 27000 | 2.700 |
1 | 10000 | 2.680 |
3 | 2022 | 2.630 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 6155 | 3 |
2.800 | 600 | 1 |
2.820 | 4001 | 1 |
2.830 | 5000 | 1 |
2.840 | 1322 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online